Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...
This second round of layoffs marks more than 300 employees let go within the year. Despite the cuts, health insurers are ...
The U. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...
Medpage Today on MSN
Over 25% of Ocular Complications From Dupilumab in Kids Developed After a Year
Of the children who received dupilumab, 8.9% developed ocular surface complications and 3.4% developed periocular involvement; 27% of these complications developed after a year, reported Sofia ...
Sanofi SNY and partner Regeneron REGN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of ...
The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for ...
MedPage Today on MSN
Adverse Event Risks Vary Among Asthma Biologics, FDA Data Show
C HICAGO -- Adverse event risks varied across biologics used by asthma patients, an analysis of data submitted to the FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback